Ophthalmic treatment device manufacturer Nova Eye Medical has reported strong sales for its glaucoma surgical device business in the four months to 31 October.
The company sold iTrack and Molteno3 devices worth $4.4 million, up from $2.6 million in the four months to 30 June when sales were affected by Covid-19 lockdowns.
iTrack is a minimally invasive glaucoma surgery consumable device while Molteno3 is a drainage device which speeds surgical procedures.
Nova Eye director Tom Spurling said the company had delivered a solid outcome despite Covid headwinds.
“The 63 per cent growth in global sales over the first wave Covid-19 period and 13 per cent growth on the same time last year is testament to the quality of our suite of products as accepted standards of care across a spectrum of glaucoma disease.”
Nova Eye Medical is developing a number of new device businesses after selling the Ellex name and ophthalmic laser and ultrasound manufacturing businesses to London’s Lumibird Group SA in July for $97.4 million.
Ellex retains its manufacturing operation in Adelaide.
Nova Eye Medical also recently established a new subsidiary, AlphaRET, to commercialise its laser technology for the treatment of intermediate age-related macular degeneration (iAMD).
Picture: Nova Eye Medical
Subscribe to our free @AuManufacturing newsletter here.